Skip to main content

ViiV Healthcare seeks USFDA approval to expand Cabenuva use for HIV-1 infected adults

Submitted by admin on
snippet

Specialist HIV company ViiV Healthcare has submitted a supplemental new drug application (sNDA) to the US Food and Drug Administration (FDA) to expand the use of Cabenuva.

Source
Pharmaceutical Business Review

ViiV Healthcare gets FDA expanded approval for HIV-1 drug Dovato

Submitted by admin on
snippet


Specialist HIV company ViiV Healthcare has secured approval from the US Food and Drug Administration (FDA) for its Dovato (dolutegravir/lamivudine) as a complete regimen to treat HIV-1 infection.

Source
Pharmaceutical Business Review

ViiV Healthcare, NIH collaborate on investigational bNAb for HIV treatment

Submitted by admin on
snippet


ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi Limited as shareholders, today announced that the company will be developing the investigational broadly neutralising antibody (bNAb) N6LS for the treatment and prevention of HIV-1, as part of an exclusive licensing agreement between GSK and the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).

Source
Pharmaceutical Business Review

ViiV Submits NDA for Once-Per-Month HIV Injectable

Submitted by admin on
snippet

HIV-focused ViiV Healthcare submitted a New Drug Application to the U.S. Food and Drug Administration (FDA) for potential approval of its investigational combination treatment for HIV-1. Submission of the NDA comes less than a month after ViiV snagged regulatory approval of Dovato.

Source
BioSpace

Gilead Sciences’ Biktarvy shows high efficacy in HIV-1 study

Submitted by admin on
snippet

Gilead Sciences has reported 96-week results from a phase 3, randomized, double-blinded study evaluating the safety and efficacy of Biktarvy (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets) for the treatment of HIV-1 infection in treatment-naïve adults.

Source
Pharmaceutical Business Review